Backed by a $200M investment from a Korean conglomerate, Vivek Ramaswamy has quietly built a ‘mother ship’ for vant creation — with a whole new strategy in mind
Vivek Ramaswamy built Roivant as the mother ship to a fleet of vants that were largely launched through in-licensing deals — often with the Big Pharma crowd as they winnowed out their pipelines. But over the past 18 months, Ramaswamy, Roivant CFO Matt Gline and the pit crew for the global biotech hatchery have been building a new mother ship with a much different biopharma flight plan in mind.
Now, after investing a “9-figure sum” into the project, they’re ready for a public launch that comes with a $200 million equity investment from SK Holdings, the investment arm of the giant Korean conglomerate SK Group.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.